Icon (NASDAQ:ICLR) Posts Earnings Results, Beats Expectations By $0.04 EPS

Icon (NASDAQ:ICLR) issued its quarterly earnings data on Tuesday. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04, FiscalAI reports. Icon had a net margin of 3.99% and a return on equity of 8.02%. The company had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the prior year, the firm earned $3.31 earnings per share. The firm’s revenue for the quarter was down .9% compared to the same quarter last year.

Icon Stock Performance

ICLR traded up $1.31 during trading on Thursday, hitting $215.47. The company’s stock had a trading volume of 711,955 shares, compared to its average volume of 1,255,970. The business’s 50 day simple moving average is $170.36 and its 200-day simple moving average is $146.19. The firm has a market cap of $16.50 billion, a PE ratio of 50.77, a P/E/G ratio of 11.98 and a beta of 1.24. Icon has a one year low of $66.57 and a one year high of $219.04. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23.

Analyst Ratings Changes

A number of brokerages have weighed in on ICLR. Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Robert W. Baird raised their price target on Icon from $210.00 to $249.00 and gave the stock an “outperform” rating in a research note on Thursday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $226.00 price objective on shares of Icon in a report on Thursday. Evercore reiterated an “outperform” rating and set a $240.00 price objective on shares of Icon in a research report on Wednesday. Finally, Truist Financial increased their target price on Icon from $209.00 to $268.00 and gave the company a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $203.00.

More Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Analyst price target raised: Robert W. Baird increased its target from $210 to $249 and reiterated an “outperform” rating, implying meaningful additional upside. Robert W. Baird stock recommendations
• Positive Sentiment: Bookings support future growth: ICON reported record net bookings of approximately $3.15 billion and signaled mid-single-digit revenue growth in 2027. Its roughly $24.5 billion backlog provides additional visibility into future revenue. ICON signals 2027 revenue expansion
• Positive Sentiment: Buybacks may support per-share value: ICON redeemed 2.36 million shares during the third quarter and indicated an expanded buyback program, which could enhance earnings per share and signal management confidence. ICON note issuance and share redemption
• Positive Sentiment: Quarterly results exceeded expectations: Third-quarter adjusted earnings were $2.66 per share versus the $2.62 consensus estimate, while revenue of $2.02 billion slightly topped expectations. ICON also raised its 2026 guidance. ICON Q3 earnings and revenues
• Neutral Sentiment: Debt restructuring: ICON completed a $2.15 billion note issuance while restructuring its debt. The financing may improve flexibility, but it also leaves investors assessing the effect of additional debt costs. ICON restructures debt
• Negative Sentiment: Year-over-year deterioration and valuation risk: Revenue declined 0.9% from the prior year, while earnings fell from $3.31 to $2.66 per share. With the stock trading at roughly 50 times earnings, some analysis argues that shares could be about 15% overvalued, potentially limiting further gains. ICON valuation analysis

Insider Activity

In other Icon news, Director Ciaran Murray sold 2,677 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $439,804.33. Following the completion of the sale, the director owned 20,452 shares of the company’s stock, valued at approximately $3,360,059.08. The trade was a 11.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Emer Lyons sold 272 shares of the company’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $182.37, for a total value of $49,604.64. Following the completion of the sale, the chief accounting officer owned 990 shares of the company’s stock, valued at approximately $180,546.30. The trade was a 21.55% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 23,068 shares of company stock worth $3,936,744. Company insiders own 44.00% of the company’s stock.

About Icon

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.